Intervet sees 6% global growth

THE NETHERLANDS - Revenues at Intervet increased by 3% to EUR 1,125 million boosted by strong autonomous growth of 6% across all regions and product lines.
calendar icon 2 March 2007
clock icon 2 minute read
Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.

In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.
© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.